Literature DB >> 26622600

Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells.

Jingjuan Zhu1, Yanbiao Zhu2, Weiwei Qi1, Wensheng Qiu1.   

Abstract

The aim of the present study was to investigate the effects of the heat shock protein (HSP)90 inhibitor AUY922 on the proliferation and migratory ability of renal cell carcinoma (RCC) cells. The expression of HSP90 was measured in vitro using western blotting and quantitative polymerase chain reaction in the ACHN and 786-O cell RCC lines, and also in the immortalized normal human proximal tubule epithelium HK-2 cell line. The effects of the time and concentration of AUY922 administration were investigated in the ACHN and 786-O cells, and the cell proliferation was measured using an MTT assay. A Transwell assay was performed to evaluate the migratory ability of ACHN cells following treatment with AUY922 at concentrations of 10, 50 and 100 nM. Western blot analysis and reverse transcription polymerase chain reaction revealed that HSP90 mRNA and protein were overexpressed in the two RCC cell lines compared with the HK-2 cell line. AUY922 inhibited the proliferation of the ACHN and 786-O cells in a time- and concentration-dependent manner, and the migratory ability of the ACHN cells was markedly suppressed subsequent to treatment with AUY922. The present data suggest that the pathogenesis of human RCC may be mediated by HSP90. It was also indicated that the specific HSP90 inhibitor AUY922 plays a therapeutic role in the treatment of RCC, and therefore, HSP90 may be a selective target for molecular-targeted treatments of RCC.

Entities:  

Keywords:  AUY922; heat shock protein 90; renal cell carcinoma; targeted therapy

Year:  2015        PMID: 26622600      PMCID: PMC4509029          DOI: 10.3892/ol.2015.3299

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

1.  17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.

Authors:  Akinori Sato; Takako Asano; Keiichi Ito; Tomohiko Asano
Journal:  Int J Oncol       Date:  2012-03-28       Impact factor: 5.650

2.  A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Authors:  Simon Pacey; Martin Gore; David Chao; Udai Banerji; James Larkin; Sarah Sarker; Karen Owen; Yasmin Asad; Florence Raynaud; Mike Walton; Ian Judson; Paul Workman; Tim Eisen
Journal:  Invest New Drugs       Date:  2010-08-05       Impact factor: 3.850

Review 3.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

Review 4.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

Review 5.  Targeted therapy in metastatic renal carcinoma.

Authors:  Jane Mattei; Rodrigo Donalisio da Silva; David Sehrt; Wilson R Molina; Fernando J Kim
Journal:  Cancer Lett       Date:  2013-11-13       Impact factor: 8.679

6.  Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.

Authors:  Sujata Patil; Nicole Ishill; John Deluca; Robert J Motzer
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

7.  Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.

Authors:  Yunze Xu; Chongyu Zhang; Dongning Chen; Juping Zhao; Zhoujun Shen; Yuxuan Wu; Yu Zhu
Journal:  Tumour Biol       Date:  2013-07-20

8.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Authors:  Suzanne A Eccles; Andy Massey; Florence I Raynaud; Swee Y Sharp; Gary Box; Melanie Valenti; Lisa Patterson; Alexis de Haven Brandon; Sharon Gowan; Frances Boxall; Wynne Aherne; Martin Rowlands; Angela Hayes; Vanessa Martins; Frederique Urban; Kathy Boxall; Chrisostomos Prodromou; Laurence Pearl; Karen James; Thomas P Matthews; Kwai-Ming Cheung; Andrew Kalusa; Keith Jones; Edward McDonald; Xavier Barril; Paul A Brough; Julie E Cansfield; Brian Dymock; Martin J Drysdale; Harry Finch; Rob Howes; Roderick E Hubbard; Alan Surgenor; Paul Webb; Mike Wood; Lisa Wright; Paul Workman
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.

Authors:  Kheem S Bisht; C Matthew Bradbury; David Mattson; Aradhana Kaushal; Anastasia Sowers; Stephanie Markovina; Karen L Ortiz; Leah K Sieck; Jennifer S Isaacs; Martin W Brechbiel; James B Mitchell; Leonard M Neckers; David Gius
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

10.  Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.

Authors:  Juping Zhao; Xin Huang; Fukang Sun; Renyi Ma; Haofei Wang; Kun Shao; Yu Zhu; Wenlong Zhou; Zhaoping Xu; Zhoujun Shen
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

View more
  1 in total

1.  Radiation induces premature chromatid separation via the miR-142-3p/Bod1 pathway in carcinoma cells.

Authors:  Dong Pan; Yarong Du; Zhenxin Ren; Yaxiong Chen; Xiaoman Li; Jufang Wang; Burong Hu
Journal:  Oncotarget       Date:  2016-09-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.